MRPL13 Promotes Tumor Cell Proliferation, Migration and EMT Process in Breast Cancer Through the PI3K-AKT-mTOR Pathway

References

• Wang S, Wang Y, Yu C. Characterization of the relationship between FLI1 and immune infiltrate level in tumour immune microenvironment for breast cancer. J Cell Mol Med. 2020.
   Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment. JAMA. 2019;321(3):316. doi:10.1001/jama.2018.2075130667503
   PubMed Web of Science ®Google Scholar
• Kalimutho M, Nones K, Srihari S, Duijf PHG, Waddell N, Khanna KK. Patterns of genomic instability in breast cancer. Trends Pharmacol Sci. 2019;40(3):198–211. doi:10.1016/j.tips.2019.01.00530736983
   PubMed Web of Science ®Google Scholar
• Zheng M, Zhou Y, Yang X, et al. High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients. Breast Cancer Res Treat. 2014;148(2):423–436. doi:10.1007/s10549-014-3172-725348432
   PubMed Web of Science ®Google Scholar
• Stefanovic S, Deutsch TM, Riethdorf S, et al. The lack of evidence for an association between cancer biomarker conversion patterns and CTC-status in patients with metastatic breast cancer. Int J Mol Sci. 2020;21(6):2161. doi:10.3390/ijms21062161
   PubMed Web of Science ®Google Scholar
• Alvarez RH, Bechara RI, Naughton MJ, Adachi JA, Reuben JM. Emerging perspectives on mTOR inhibitor-associated pneumonitis in breast cancer. Oncologist. 2018;23(6):660–669. doi:10.1634/theoncologist.2017-034329487226
   PubMed Web of Science ®Google Scholar
• McKenna M, McGarrigle S, Pidgeon GP. The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. Biochim Biophys Acta Rev Cancer. 2018;1870(2):185–197.30318472
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Dickler MN. Estrogen receptor-positive breast cancer: exploiting signaling pathways implicated in endocrine resistance. Oncologist. 2018;23(5):528–539. doi:10.1634/theoncologist.2017-042329352052
   PubMed Web of Science ®Google Scholar
• Piatyszek MA, Denslow ND, O’Brien TW. RNA binding proteins of the large subunit of bovine mitochondrial ribosomes. Nucleic Acids Res. 1988;16(6):2565–2583. doi:10.1093/nar/16.6.25653129699
   PubMed Web of Science ®Google Scholar
• Lee Y-K, Lim JJ, Jeoun U-W, et al. Lactate-mediated mitoribosomal defects impair mitochondrial oxidative phosphorylation and promote hepatoma cell invasiveness. J Biol Chem. 2017;292(49):20208–20217. doi:10.1074/jbc.M117.80901228978646
   PubMed Web of Science ®Google Scholar
• Dass S, Mather MW, Ke H. Divergent mitochondrial ribosomes in unicellular parasitic protozoans. Trends Parasitol. 2020;36(4):318–321. doi:10.1016/j.pt.2020.01.00232191848
   PubMed Web of Science ®Google Scholar
• Porporato PE, Filigheddu N, Pedro JMB-S, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28(3):265–280.29219147
   PubMed Web of Science ®Google Scholar
• Kim H-J, Maiti P, Barrientos A. Mitochondrial ribosomes in cancer. Semin Cancer Biol. 2017;47:67–81. doi:10.1016/j.semcancer.2017.04.00428445780
   PubMed Web of Science ®Google Scholar
• Yoo YA, Kim MJ, Park JK, et al. Mitochondrial ribosomal protein L41 suppresses cell growth in association with p53 and p27Kip1. Mol Cell Biol. 2005;25(15):6603–6616. doi:10.1128/MCB.25.15.6603-6616.200516024796
   PubMed Web of Science ®Google Scholar
• Liu L, Luo C, Luo Y, et al. MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression. Oncogene. 2018;37(1):86–94. doi:10.1038/onc.2017.31428869607
   PubMed Web of Science ®Google Scholar
• Best CJM, Gillespie JW, Yi Y, et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res. 2005;11(19 Pt 1):6823–6834. doi:10.1158/1078-0432.CCR-05-058516203770
   PubMed Web of Science ®Google Scholar
• Pedersen IS, Thomassen M, Tan Q, et al. Differential effect of surgical manipulation on gene expression in normal breast tissue and breast tumor tissue. Mol Med. 2018;24(1):57. doi:10.1186/s10020-018-0058-x30445902
   PubMed Web of Science ®Google Scholar
• Dhage S, Ernlund A, Ruggles K, et al. A genomic ruler to assess oncogenic transition between breast tumor and stroma. PLoS One. 2018;13(10):e0205602. doi:10.1371/journal.pone.020560230325954
   PubMed Web of Science ®Google Scholar
• Clarke C, Madden SF, Doolan P, et al. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis. 2013;34(10):2300–2308. doi:10.1093/carcin/bgt20823740839
   PubMed Web of Science ®Google Scholar
• Kretschmer C, Conradi A, Kemmner W, Sterner-Kock A. Latent transforming growth factor binding protein 4 (LTBP4) is downregulated in mouse and human DCIS and mammary carcinomas. Cell Oncol (Dordr). 2011;34(5):419–434. doi:10.1007/s13402-011-0023-y21468687
   PubMed Web of Science ®Google Scholar
• Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W. Identification of early molecular markers for breast cancer. Mol Cancer. 2011;10(1):15. doi:10.1186/1476-4598-10-1521314937
   PubMed Web of Science ®Google Scholar
• Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227. doi:10.1038/s41598-018-27521-y29907753
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-009522588877
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. doi:10.1073/pnas.050658010216199517
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.126211846609
   PubMed Web of Science ®Google Scholar
• Zarrei M, MacDonald JR, Merico D, Scherer SW. A copy number variation map of the human genome. Nat Rev Genet. 2015;16(3):172–183. doi:10.1038/nrg387125645873
   PubMed Web of Science ®Google Scholar
• Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, et al. Mitochondria “fuel” breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. Cell Cycle. 2012;11(23):4390–4401. doi:10.4161/cc.2277723172368
   PubMed Web of Science ®Google Scholar
• Sharma MR, Koc EC, Datta PP, Booth TM, Spremulli LL, Agrawal RK. Structure of the mammalian mitochondrial ribosome reveals an expanded functional role for its component proteins. Cell. 2003;115(1):97–108. doi:10.1016/S0092-8674(03)00762-114532006
   PubMed Web of Science ®Google Scholar
• Cavdar Koc E, Ranasinghe A, Burkhart W, et al. A new face on apoptosis: death-associated protein 3 and PDCD9 are mitochondrial ribosomal proteins. FEBS Lett. 2001;492(1–2):166–170. doi:10.1016/S0014-5793(01)02250-511248257
   PubMed Web of Science ®Google Scholar
• Greber BJ, Ban N. Structure and function of the mitochondrial ribosome. Annu Rev Biochem. 2016;85(1):103–132. doi:10.1146/annurev-biochem-060815-01434327023846
   PubMed Web of Science ®Google Scholar
• Johnson J, Thijssen B, McDermott U, Garnett M, Wessels LFA, Bernards R. Targeting the RB-E2F pathway in breast cancer. Oncogene. 2016;35(37):4829–4835. doi:10.1038/onc.2016.3226923330
   PubMed Web of Science ®Google Scholar
• Majidinia M, Yousefi B. DNA repair and damage pathways in breast cancer development and therapy. DNA Repair (Amst). 2017;54:22–29. doi:10.1016/j.dnarep.2017.03.00928437752
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim HD, Kim J. Cytoplasmic ribosomal protein S3 (rpS3) plays a pivotal role in mitochondrial DNA damage surveillance. Biochim Biophys Acta. 2013;1833(12):2943–2952. doi:10.1016/j.bbamcr.2013.07.01523911537
   PubMed Web of Science ®Google Scholar
• Hsu TYT, Simon LM, Neill NJ, et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015;525(7569):384–388. doi:10.1038/nature1498526331541
   PubMed Web of Science ®Google Scholar
• Zhou X, Jiang Z. STING-mediated DNA sensing in cancer immunotherapy. Sci China Life Sci. 2017;60(6):563–574. doi:10.1007/s11427-016-9066-028639100
   PubMed Web of Science ®Google Scholar
• Nieto MA. Epithelial-mesenchymal transitions in development and disease: old views and new perspectives. Int J Dev Biol. 2009;53(8–10):1541–1547. doi:10.1387/ijdb.072410mn19247945
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166(1):21–45.27368099
   PubMed Web of Science ®Google Scholar
• Li Y, Wang T, Sun Y, et al. p53-Mediated PI3K/AKT/mTOR pathway played a role in ptox-induced EMT inhibition in liver cancer cell lines. Oxid Med Cell Longev. 2019;2019:2531493.31191795
   PubMed Web of Science ®Google Scholar
• Katsuno Y, Meyer DS, Zhang Z, et al. Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. Sci Signal. 2019;12(570):570. doi:10.1126/scisignal.aau8544
   Web of Science ®Google Scholar
• Baek SH, Ko J-H, Lee JH, et al. Ginkgolic acid inhibits invasion and migration and TGF-β-induced EMT of lung cancer cells through pi3k/Akt/mTOR inactivation. J Cell Physiol. 2017;232(2):346–354. doi:10.1002/jcp.2542627177359
   PubMed Web of Science ®Google Scholar
• Yang F, Takagaki Y, Yoshitomi Y, et al. Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis. Cancer Res. 2019;79(4):735–746. doi:10.1158/0008-5472.CAN-18-062030584072
   PubMed Web of Science ®Google Scholar
• Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741–4751. doi:10.1038/onc.2010.21520531305
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–715. doi:10.1016/j.cell.2008.03.02718485877
   PubMed Web of Science ®Google Scholar